drugset
drugset / Trial / NCT02956512

Phase I Study to Evaluate the Safety of Dexibuprofen 300mg Under Fasting and Fed Conditions

NCT02956512 ↗

Phase 1 Completed 52 enrolled Apsen Farmaceutica S.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

Phase I Study to Evaluate the Safety of Dexibuprofen 300mg (Apsen Pharmaceuticals A / S.) After a Single and Multiple Dose Oral Administration in Healthy Participants of Both Sexes Under Fasting and Fed Conditions.

Timeline

Start
2019-03-18
Primary completion
2019-07-12
Completion
2019-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexibuprofen Small molecule 300 mg Oral

Indications

No indication recorded.